Anal. Calcd for  $C_{36}H_{40}O_4N_4Cl_2$ : C, 65.2; H, 6.0; N, 8.5. Found: C, 65.0; H, 6.1; N, 8.3.

1,4,5,8-Tetramethyl-2,3-vinyl-6,7-bis( $\beta$ -methoxycarbonylethy1)porphine (Protoporphyrin **111** Dimethyl Ester) (5). Methanol saturated with zinc acetate (11 mL) was added to a solution of the  $\beta$ -chloroethylporphyrin 23 (64 mg) in 30 mL of dry methylene chloride. The mixture was warmed to 35 "C for a while, and then poured over 100 mL of water. The organic layer was separated, washed with aqueous sodium acetate, then with water, dried  $(Na<sub>2</sub>SO<sub>4</sub>)$ , and evaporated to dryness. The residue was dissolved in 10 mL of dry tetrahydrofuran, and 30 mL of a 1 M solution of potassium tertbutoxide in tert-butyl alcohol was added. The mixture was kept in a sealed vessel under vacuum (50  $\mu$ ) during 96 h at 20 °C. The vessel was then opened, the mixture was poured into water (200 mL), and the solution was adjusted to pH 6 with glacial acetic acid, then extracted with 1% pyridine in methylene chloride (3 *X* 60 mL). The organic extracts were dried (Na<sub>2</sub>SO<sub>4</sub>) and evaporated to dryness, and the residue was dissolved in 70 mL of 5% sulfuric acid in methanol. After keeping overnight at 20 °C in the dark, chloroform (300 mL) was added and the mixture was washed with aqueous sodium acetate, then with a sodium bicarbonate solution, and finally with water. The organic layer was dried (Na<sub>2</sub>SO<sub>4</sub>), evaporated to dryness, and purified by chromatography through a TLC silica gel column using 0.5% methanol in chloroform as eluent. The eluates were evaporated to dryness and the residue was crystallized from methylene chloridehexane: 35 mg (60%); mp 262-264 °C (lit.<sup>8</sup> mp 276 °C); visible max spectrum (CDCl<sub>3</sub>) 404 nm ( $\epsilon$  114 000), 502 (9500), 538 (6400), 574 (4000), 626 (2400); NMR (0.05 M, CDCl<sub>3</sub>) 3.25 (m, 4, CH<sub>2</sub>CO), 3.56  $(b, 12, CH_3), 3.70$  (s, 6, OCH<sub>3</sub>), 4.35 (m, 4, CH<sub>2</sub>CH<sub>2</sub>CO), 6.3 (m, 4,  $=$ CH<sub>2</sub>), 8.15 (m, 2,  $=$ CH), 9.93, 10.00 ppm (b, b, 4, meso  $=$ CH); MS  $m/e$  590 (M<sup>+</sup>, 100%), 517 (M – CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, 70%).

Anal. Calcd for  $C_{36}H_{38}O_4N_4$ ; C, 73.2; H, 6.5; N, 9.5. Found: C, 73.1; H, 6.6; N, 9.4.

1,4-Vinyl-2,3,5,8-tetramethyl-6,7-bis(β-methoxycarbonylethy1)porphine (Porphyrin **XI11** Dimethyl Ester) (3). The bis(pchloroethy1)porphyrin 17 (62 mg) was vinylated with potassium tert-butoxide as described in the preparation of *5.* After the purification by chromatography the protoporphyrin dimethyl ester 3 was crystallized from methylene chloride-hexane: 30 mg (55%); mp 208-210 "C (lit.5 mp 198-200 "C); visible max (CDCl3) 408 nm *(e*  117 *OOO),* 506 (10 000),540 (SOOO), 576 (4400), 630 (3500) (see ref 13 for visible max of the same product obtained by incubation of coproporphyrinogen **IV** with duck blood erythrocytes); NMR (0.05 8, CH<sub>2</sub>CH<sub>2</sub>CO), 6.18, 8.20 (m, m, 6, CH=CH<sub>2</sub>), 9.58, 9.76, 9.86 (s, s, 8, CH<sub>2</sub>CH<sub>2</sub>CO), 6.18, 8.20 (m, m, 6, CH=CH<sub>2</sub>), 9.58, 9.76, 9.86 (s, s, s, 1, 1, 2, meso =CH). *MS*|*m*/e 590 (M<sup>+</sup>, 70%), 517 (M – CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, M, CDC13) 3.35, 3.43 (s, S. 12, CH?), 3.62 **(s,** 6, OCHS), 3.12, 4.22 (t, t, s, 1, 1, 2, meso = CH). MS $m/e$  590 (M<sup>+</sup>, 70%),<br>50%), 416 (M – 2CH<sub>2</sub>CH<sub>2</sub>CO<sub>2</sub>CH<sub>3</sub>, 80%).

Anal. Calcd for  $C_{36}H_{38}O_4N_4$ : C, 73.2; H, 6.5; N, 9.5. Found: C, 73.1; H, 6.6: N, 9.3.

Acknowledgments. This work was generously supported by grants of the National Institutes of Health (GM **11973)** and the Consejo Nacional de Investigaciones (Argentina). We thank Professor A. H. Jackson (Cardiff) for helpful exchange of information.

Registry **No.-&** 59969-40-3; 5, 7034-33-5; 7, 4792-10-3; 8, 54278-18-1; 9,53700-88-2; 10, 6122-77-6; 11, 63089-12-3; 12,63089- 13-4; 13,63089-14-5; 14,63089-15-6; 15,63122-48-5; 16,63089-16-7; 17, 63089-17-8; **19,** 37945-74-7; 20, 63089-18-9; 21, 63089-19-0; 23, 63089-20-3; 24, 52091-12-0; 25, 52091-13-1; 26, 53727-79-0; 27, 63089-21-4; 28,63089-22-5; 29,63089-23-6.

#### References **and** Notes

- 
- (1) J. Kruh and H. Borsook, *J. Biol. Chem.*, **220**, 905 (1956); G. P. Bruns and<br>(2) M. London, *Biochim. Biophys. Res. Commun., 18, 236 (1965).*<br>(2) M. B. Mathews, T. Hunt, and A. Brayley, *Nature (London), New Biol.*, **2**
- (1973).<br>
(3) B. F. Burnham in "Metabolic Pathways", Vol. III, 3rd ed, D. M. Greenberg,<br>
Ed., Academic Press, New York, N.Y., 1969.<br>
(4) R. B. Frydman and B. Frydman, FEBS Lett., 52, 317 (1975).<br>
(5) H. M. G. Al-Hazimi, A.
- 
- 
- 
- **(1976). (7)** H. Fischer and H. Orth, "Die Chemie des Fyrrols", Vol. 11, Akad. Verlags- aeselischaft. LeiDzia. **1937, p 453. (8)** heference **7,** p **405:**
- **(9)** J. A. **S.** Cavaleiro. G. W. Kenner, and K. M. Smith, *J.* Chem. SOC., Perkin Trans. 1, **2478 (1973).**
- **(10)** J. A. **S.** Cavaleiro, G. **W.** Kenner, and K. M. Smith, *J.* Chem. *SOC.,* Perkin Trans. **1, 1188 (1974).**
- (1 **1)** G. Buldain, J. Hurst, R. B. Frydman, and B. Frydman, *J. Org.* Chem., preceding paper in **this** *issue.*
- **(12)** A. Valasinas and B. Frydman, *J.* Org. Chem., **41, 2991 (1976).**
- 
- 
- (13) B. Frydman, R. B. Frydman, A. Valasinas, E. S. Levy, and G. Feinstein, *Philos. Trans. R. Soc. London, Ser. B*, 273, 137 (1976).<br>(14) J. A. S. Cavaleiro, A. M. d'A Rocha Gonsalves, G. W. Kenner, and K. M. Smith, J. Ch taken as noted. Microanalyses were performed by the Alfred Bernhardt<br>Mikroanalytisches Laboratorium (Elbach). The silica gel used for column chromatography was Kieselgel G (Fluka AG). TLC was performed on pre-<br>coated silica gel 60 F-254 plaques (Merck, Darmstadt). The substances<br>were spotted when necessary by spraying with Ehrlich's reagent (2% p-<br>dimethylamin
- Chem. *SOC.,* **93, 2738 (1971).**
- 
- **(17) S.** F. MacDonald, *J.* Chem. *SOC.,* **4184 (1952). (18)** R. P. Carr, A. H. Jackson, G. **W.** Kenner. and *G.* S. Sach, *J.* Chem. **SOC.** C, **487 (1971).**

# **Aldol Condensations of Regiospecific Penicillanate and Cephalosporanate Enolates. Hydroxyethylation at C-6 and C-7**

# Frank DiNinno,\* Thomas R. Beattie, and B. G. Christensen

Merck Sharp & Dohme Research Laboratories, Division *of* Merck & Co., Inc., *P.O. Box* 2000, Rahway, *New* Jersey 07065

### Received February *22,* 1977

Enolates derived from 6a-bromo- or 6a-iodopenicillanates, 6,6-dibromopenicillanate, and 7a-iodocephalosporanate have been generated in situ by a metal-halogen exchange process at  $-78$  °C using either *n*-butyllithium or methylmagnesium bromide and reacted with acetaldehyde to yield aldols. The condensations consistently provided diastereomeric mixtures of hydroxyethylated products at the  $\alpha$  face of the  $\beta$ -lactam nucleus and a single diastereomer at the  $\beta$  face. The absolute configuration of one such diastereomer, benzyl  $6\alpha$ -bromo-6 $\beta$ -(1'-hydroxyethyUpenicillanate **(sa),** was determined by x-ray analysis of its tert- butyldimethylsilyl derivative 9. Subsequent reduction of these bromohydrins with zinc-silver couple in methanol or methanolic acetic acid and GLC analysis of the resulting purified products as their trimethylsilyl ether derivatives lead to the absolute structures of benzyl 64 **1'-hydroxyethyl)penicillanates** 484.

Thienamycin  $(1)$ , a highly active  $\beta$ -lactam antibiotic recently discovered in these laboratories, $<sup>1</sup>$  has several features</sup> which distinguish it from the more familiar penicillins **2** and cephalosporins **3.** In particular, the hydroxyethyl2 side chain

 $\alpha$  to the lactam carbonyl at C-6 is unusual, as generally this substituent is an amide moiety in naturally occurring penicillins and cephalosporins.

We were therefore interested in preparing the hybrid



6(7)-hydroxyethyl substituted penicillins **4** and cephalosporins **5** to compare their chemical, physical, and antibacterial properties, and we report herein details of our findings.



#### **Results** and **Discussion**

At the time this work was initiated, the relative stereochemistry of thienamycin was unknown. Accordingly, any solution to the introduction of the hydroxyethyl function should reflect the production of as many of the four possible stereoisomers at the designated centers.

Typically,  $\beta$ -hydroxycarbonyl systems are generated by use of an aldol or Reformatsky reaction, but few examples of the prerequisite penicillin and cephalosporin enolates **6** (wherein  $X = H$  or a reducible equivalent) have appeared in the literature.3



The mention<sup>5</sup> without comment or experimental detail that methyl 6-bromopenicillanate formed from methyl 6,6-dibromopenicillanate upon reaction with 1 equiv of butyllithium seemed to us to be a possible case of penicillin enolate formation.6 We have exploited this idea of metal-halogen exchange as a first step in a sequence which leads to all four of the possible penicillin isomers  $4 (R = CH_2Ph)$  (Scheme I).

Treatment of an anhydrous tetrahydrofuran solution of benzyl 6,6-dibromopenicillanate **(7)** with 1 equiv of either n-butyllithium in hexane or methylmagnesium bromide in ether gave upon reaction with excess acetaldehyde a mixture of three bromohydrins 8a-c. Yields were 30-40% when produced with n-butyllithium and 95% with methylmagnesium bromide. The mixture **was** separable by multiple elution plate layer chromatography into 8a and a mixture of **8b,c.** The configuration of the bromine atom of isomer **8a** was assigned as  $\alpha$  based on the observed downfield shift of the C-5 proton in the NMR spectrum of **8a** as compared to diastereomers **8b**  and *8c* using the argument previously advanced by Cama et al.7 See Table I. Absolute confirmation **of** the structural as-



signment of 8a was afforded by the single crystal x-ray analysiss of its *tert-* butyldimethylsilyl ether derivative **9** prepared by the method of Corey and Venkateswarlu.<sup>9</sup> A stereoview of this compound is depicted in Figure 1.



As depicted in Scheme I, removal of the bromine from 8a and 8b,c was accomplished with zinc-silver couple<sup>10</sup> in methanol or methanol-ccetic acid to provide the designated mixtures of isomers  $4 (R = CH_2Ph)^{11}$  Although not obvious by TLC, it was clear from NMR data that mixtures of isomers of **4** were present. Quantitative composition of each purified reduction sample could be determined by conversion of an aliquot with **N,O-bis(trimethylsily1)trifluoroacetamide**  (BSTFA) to the corresponding monotrimethylsilyl derivatives and analysis by gas-liquid Chromatography wherein the four isomers 4a-d had different retention times. Table I1 indicates the product ratios found.

When benzyl 6 $\alpha$ -bromopenicillanate (10a) was substituted for dibromide **7** a mixture of isomers  $4 (R = CH_2Ph)$  could be obtained directly in very low yield (Scheme 11). Analogously, the use of the corresponding iodopenicillanate **10b** afforded yields **of** isomers **4** in the range of **0-21%** when the metal-





 $a$  All shifts are measured in CDCl, and are reported in  $\delta$  ppm downfield from Me<sub>4</sub>Si, followed by multiplicity and coupling constants J: s, singlet; d, doublet; dd, doublet of doublets; *q,* quartet; m, multiplet. *b* Measured in Me,CO-d,.



Figure **1. ORTEP** drawing of molecule **9.** 

halogen exchange reaction was conducted in THF. This situation was improved considerably when the solvent was changed to ethyl ether and **4a,4b,** and **4d** could be obtained in consistent yields of about *50%.* Optimally, this mixture could be produced in *80%* yield by the action of methylmagnesium bromide instead of BuLi in THF solvent. See Table **I1** for isomer composition.

Scheme **I1**  *"PX* **2.MeCHO**   $X$  H  $\qquad \qquad \blacksquare$ 1. **BuLi** HO%% HC *<sup>0</sup>***3. K+** *<sup>0</sup>*! CO,CH,Ph CO,CH,Ph 10a,  $X = Br$  $+4b+4d$  $\mathbf{b}$ ,  $\mathbf{X} = \mathbf{I}$ 





*a* 0.5 equiv of HOAc added. <sup>b</sup> 2.5 equiv of HOAc added. <sup>c</sup> 2.64 equiv of HOAc added. d Reactions carried out in THF **as** reaction scale increased, yield decreased. <sup>e</sup> Reactions conducted in Et<sub>2</sub>O. *<sup>f</sup>*Metal-halogen exchange performed with MeMgBr in THF.

Having accomplished the objective of preparing all four isomers of penicillanate **4,** the problem of isomer separation was undertaken. In any TLC solvent system examined only a single spot was observed with every isomers **4** mixture. GC separation of the trimethylsilyl derivatives of **4** was satisfactory on an analytical scale but judged impractical on a preparative scale. However, through the use of high-pressure liquid chromatography (HPLC) a system was developed in which trans diastereomers **4a** and **4b** appeared **as** one peak and cis diastereomers **4c** and **4d** appeared **as** another. By using samples enriched in a given isomer together with the HPLC techniques of recycling and *peak* shaving, pure samples of each isomer were obtained. Table I contains the **NMR** data for the four individual isomers.

The separate benzyl ester isomers **4a-d** were smoothly

Penicillanate and Cephalosporanate Enolates *J. Org. Chem., Vol. 42, No. 18,1977* **2963** 

converted into the corresponding carboxylic acids **4a-d** (R = H) by hydrogenation over **10%** palladium on carbon. Table I summarizes the pertinent NMR data of these antibiotics. Each isomer was tested as the sodium salt against a variety of bacteria. The two trans diastereomers **4a** and **4b** were essentially equiactive but substantially less active than the corresponding cis diastereomers **4c** and **4d** which were also essentially equiactive. All, however, were markedly less active than benzylpenicillin.

Finally, the cephalosporin derivatives  $5 (R = CMe<sub>3</sub>)$  were analogously obtained as outlined in Scheme 111. Exposure of



tert-butyl  $7\alpha$ -iodo-3-acetoxymethyl- $\Delta$ <sup>3</sup>-cephalosporanate (11) to ethereal MeMgBr as before provided a 42% yield of a separable mixture of **5a,h** and **5d** in a respective ratio of **1.5:l.O.**  A pure sample of the major trans diastereomer **5a** could be obtained by fractional crystallization and subsequent HPLC. (See Table I for NMR data.) Isomers **5a** and **5d** were converted to the corresponding sodium salts by sequential treatment with trifluoroacetic acid and sodium bicarbonate. These materials were found to be almost completely devoid of antibacterial activity. Although no attempt was made to rigorously assign a configuration to the hydroxyethyl side chain of **5a** and **5d,** it is most probable by analogy to the penicillin examples and the argument that follows that both of these compounds possessed the  $R$  configuration.

In conclusion, it is noteworthy that in a variety of hydroxyalkylations13 performed as depicted in Scheme I1 with aldehydic substrates, only a *single 60-hydroxyalkyl penicillunate diastereomer* could be detected. This observation can be rationalized in terms of steric hindrance of substrate approach to the more sterically hindered face of the benzylpenicillanate with concomitant coordination of the aldehyde carbonyl oxygen atom to the metal of the enolate,  $14$  viz., 12.



Molecular models clearly show a severe steric interaction of the aldehyde R' group with the thiazolidine ring and the C- $2\beta$ -Me group when it occupied the alternate conformation depicted in 12. Such a postulate is also consistent with the observed (R) configuration of the **6/3-hydroxyethylpenicilla**nates  $4d$   $(R = CH_2Ph)$  and  $8a$  generated by  $12$   $(R = H$  and  $Br$ , respectively). The demand of a rigid geometry for this  $\beta$  substituent is reflected by the magnitude of the coupling constant for the *6a* proton and the methine proton of the ethanol group in compounds  $4c$  and  $4d$   $(R = CH_2Ph)$ . [Compare the analogous couplings in  $4a$  and  $4b$   $(R = CH_2Ph)$  in Table I.] As a further test of this hypothesis, replacement of acetaldehyde by acetone as in Scheme I1 should then exclusively produce the *6a* 2'-propanol adduct. Indeed, this was found to be the case in repetitive, carefully examined experiments.

#### **Experimental Section**

Melting points were determined on a Thomas-Hoover capillary melting point apparatus and are uncorrected. Infrared spectra were recorded in chloroform solution or as a thin film on a Perkin-Elmer 137 infrared spectrophotometer. Only selected absorptions are reported. The NMR spectra were recorded on either a Varian T-60 or HA-100 spectrometer. Tetramethylsilane was used as an internal standard and chemical shifts are reported in parts per million (6) relative to Me4Si. Deuteriochloroform was used as solvent unless indicated otherwise. Mass spectra were obtained on an LKB go00 gas chromatograph-mass spectrometer at 70 eV. Only the most abundant and/or significant ions are given. Gas chromatographic analyses were performed on a Varian Aerograph Series 1200 instrument equipped with flame ionization detectors and helium was used as the carrier gas with a flow rate of 25 mL/min. Stainless steel columns (5 ft  $\times$  0.125 in.) packed with 5% SE-30 on 100/120 Variport were employed for analyses. High-pressure liquid chromatographic analyses were performed on a Waters Associates ALC/GPC 244 apparatus using Porosil A columns and Burdick and Jackson "distilled in glass" UV grade acetonitrile and chloroform. The progress of reactions was generally followed by TLC on Analtech silica gel GF 254 plates using UV and ceric sulfate spray followed by heating to detect spots. Plate layer chromatography (PLC) was performed on either Analtech silica gel GF  $20 \times 20$  cm or  $20 \times 40$  cm plates. Column chromatography was conducted with Baker silica gel 60-200 mesh. Tetrahydrofuran and diethyl ether were freshly distilled from benzophenone ketyl. Butyllithium (Ventron Corp.) was titrated periodically using the **sec**butyl alcohol/biquinoline method. Methylmagnesium bromide in ether (2.9 M) was used as supplied by Ventron Corp. N,O-Bis(trimethylsily1)trifluoroacetamide (BSTFA) was purchased from Supelco, Inc.

Preparation **of** Benzyl **6,6-Dibromopenicillanate (7).'** To a stirred solution of freshly prepared benzyl diazopenicillanate<sup>15</sup> (9.9 g, 31 mmol) in 300 mL of methylene chloride at -40 °C under a nitrogen atmosphere was added dropwise a solution of bromine (5 g, 31 mmol) in 50 mL of methylene chloride over 55 min. The mixture was let warm to 0 °C over 45 min and evaporated under reduced pressure. The residue was purified by chromatography and eluted withbbenzene to give 6.2 g (44%) of **7.** Recrystallization from 2-propanol gave mp 78.5-79 °C dec: IR 1792, 1740 cm<sup>-1</sup>; NMR  $\delta$  1.36 (s, 3 H), 1.6 (s,  $3 \text{ H}$ ), 4.53 (s, 1 H), 5.16 (s, 2 H), 5.76 (s, 1 H), 7.33 (s, 5 H).

Anal. Calcd for  $\rm C_{15}H_{15}NO_3SBr_2$ : C, 40.11; H, 3.37; N, 3.12; Br, 35.58. Found: C, 40.19; H, 3.27; N, *3.20;* Br, 35.68.

Preparation of Benzyl  $6\alpha$ -Bromopenicillanate (10a). To a stirred mixture of freshly prepared benzyl diazopenicillanate<sup>15</sup> [derived from 1.59 g of (3 mmol) of benzyl 6-aminopenicillanate p-toluenesulfonic acid salt] and potassium bromide (1.0 g, 8.4 mmol) in 150 mL of acetone at  $0°C$  in an ice-water bath was added dropwise 10 mL of *1* N hydrobromic acid. The mixture was stirred at 0 "C for 40 min and 1.5 g of NaHC03 was added. This mixture was stirred at 0 **"C** for 20 min, filtered, and evaporated. The residue obtained was partitioned between water and benzene and the benzene extract dried over NazSO4, filtered, and evaporated. Purification by column chromatography eluted with benzene provided  $0.73$  g (59%) of 10a: pale yellow **oil;NMRd1.38(~,3H),1.58(~,3H),4.52(s,lH),4.76(d,J=** 1.5Hz, 1 **H),** 5.14 (s,2 H), 5.38 (d, *J* = 1.5 Hz), 7.3 (s,5 H).

Preparation of Benzyl  $6\alpha$ -Iodopenicillanate (10b). As described above, a solution of benzyl diazopenicillanate in 100 mL of acetone was stirred in an ice-water bath and treated dropwise with a solution of  $2.0 g$  (13.1 mmol) of NaI, 1.3 mL of 57% HI, and 10 mL of water over 35 min. The mixture was stirred at  $0 °C$  for 1 h, 2 g of NaHCO<sub>3</sub> was added, and the mixture was stirred for 15 min longer. The acetone was removed under reduced pressure and the residue was partitioned between benzene and  $H_2O$ . The benzene layer was separated, washed with aqueous sodium thiosulfate solution, dried over MgS04, and evaporated. The residue was chromatographed eluting with benzene to give 0.87 g (63%) of 10b as **Q** pale yellow oil: IR 1780, 1740 cm-'; NMR δ 1.33 (s, 3 H), 1.53 (s, 3 H), 4.5 (s, 1 H), 4.92 (d, *J* = 1.5 Hz, 1 H), 5.12 (s, 2 H), 5.42 (d,  $J = 1.5$  Hz, 1 H), 7.3 (s, 5 H); mass spectrum  $m/e$ 417 (M+), 389,250,227.

Formation of Benzyl 6-Bromo-6-(1'-hydroxyethyl)penicil**lanates (8a and 8b,c). A. Reaction of 7 with MeMgBr.** To a stirred solution of 449 mg (1.0 mmol) of benzyl **6,6-dibromopenicillanate (7)**  in 25 mL of dry THF at  $-78$  °C under nitrogen was added dropwise  $345 \mu L$  (1.0 mmol) of ethereal methylmagnesium bromide and the mixture was stirred for 20 min. To the stirred, colorless solution at -78 °C under N<sub>2</sub> was added 300  $\mu$ L (5.3 mmol) of neat acetaldehyde and the solution was stirred for 20 min. The reaction was quenched at  $-78$  °C with 2 mL of saturated aqueous NH<sub>4</sub>Cl, and partitioned between  $Et_2O$  and  $H_2O$ . The organic phase was separated, washed with brine, dried with MgS04, filtered, and evaporated. Purification of the colorless, oily residue by PLC [one development,  $C_6H_6-EtOAc$ (4:l)j gave 80 mg of recovered dibromide **(7)** and 326.5 mg (96%) of a mixture of bromohydrins **8a-c.** Separation was effected by PLC [three developments,  $CH<sub>2</sub>Cl<sub>2</sub>$ -EtOAc (50:1)] to provide 230.5 mg of benzyl 6a-bromo-68-[(R)-1'-hydroxyethyl]penicillanate (8a) which slowly crystallized [mp 63-64 °C; IR 3600-3200, 1783, 1748 cm<sup>-1</sup> NMR, see Table I; mass spectrum *m/e* 415,413 (M+), 334,250,225, 223, 166,164,114,911 and 81 mg of a mixture of bromohydrins **8b,c**  as a light yellow oil [IR 3600-3200,1783,1748 cm-l; NMR, see Table I; mass spectrum *m/e* 415,413 (M+), 334,250,225,223,166,154,114, 91; GC-mass spectrum of separated MesSi derivatives in order of emergence  $m/e$  487, 485 (16), 472, 470 (16), 406 (5), 250 (32), 222, 220 (32), 157 (21), 91 (100), and 487, 485 (12), 472, 470 (12), 406 (7), 250  $(26), 222, 220 (26), 157 (17), 91 (100)$ .

**B. Reaction of 7 with BuLi.** To a stirred solution of **7** (3.5 g, 7.75 mmol) in 80 mL of anhydrous THF at  $-70$  °C under nitrogen atmosphere was added dropwise 3.25 mL of a 2.38 M solution of butyllithium in hexane. The mixture was stirred for 10 min and a solution of acetaldehyde (0.36 g, 8.25 mmol) in 2.4 mL of anhydrous THF was added. The resulting mixture was stirred at  $-70$  °C under nitrogen atmosphere for 15 min and the reaction was quenched with 10 mL of a saturated aqueous NH4Cl solution. The cold solution was filtered and the filtrate was concentrated under reduced pressure. The concentrate was partitioned between chloroform and aqueous brine and the organic phase was separated, dried with MgSO<sub>4</sub>, filtered, and evaporated. Purification by chromatography gave 1.3 g (41%) of **8a-c.**  Separation as above gave 585 mg of **8a16** and 297 mg of **8b,c.** 

Formation of Benzyl 6a-Bromo-6 $\beta$ -[(R)-1'-tert-butyldi**methylsiloxyethyl]penicillanate (9).** A mixture of crude **8a16** (133.5 mg, ca. 0.3 mmol) and 2 mL of a stock solution comprised of 10 mmol of **tert-butyldimethylchlorosilaneg** and 25 mmol of imidazole in 10 mL of dry DMF was heated at 55 °C under  $\mathrm{N}_2$  for 5 h. The cooled mixture was poured into 25 mL of  $H_2O$  and 20 mL of  $Et_2O$ . The layers were separated and the aqueous phase further extracted with 20 mL of Et<sub>2</sub>O. The ether extracts were combined, washed with H<sub>2</sub>O (2  $\times$  $10 \text{ mL}$ ), dried (MgSO<sub>4</sub>), filtered, and evaporated. Purification by PLC [one development, CHCl<sub>3</sub>-hexane (1.5:1)] provided 92 mg (ca. 54%) of **9:** mp 89.5-90 "C (2-propanol); IR 1788,1730 cm-'; NMR 6 0.083  $(s, 6 H)$ , 0.92  $(s, 9 H)$ , 1.18  $(d, J = 6 Hz, 3 H)$ , 1.37  $(s, 3 H)$ , 1.57  $(s, 3 H)$ ,  $4.17$  (q,  $J = 6$  Hz, 1 H),  $4.23$  (s, 1 H),  $5.17$  (s, 2 H),  $5.47$  (s, 1 H),  $7.33$  (s, 5 H); mass spectrum *m/e* 514,512,472,470,422,420,392,250, 241, 239, 221, 219,91.

Anal. Calcd for C<sub>23</sub>H<sub>34</sub>BrNO<sub>4</sub>SSi: C, 52.26; H, 6.48; N, 2.65; Br, 5.12. Found: C, 52.32; H, 6.18; N, 2.44; Br, 15.48.

**Formation of Benzyl 6a- and 6@-[ (R)-1'-Hydroxyethyllpenicillanates (4a and 4d). Reduction of 8a.** To a stirred suspension of excess zinc-silver couple<sup>10</sup> in 0.5 mL of MeOH at room temperature was added a solution of **8a** (35 mg, 0.084 mmol) in 1 mL of MeOH. The mixture was stirred under an atmosphere of  $N_2$  for 1.25 h. The excess couple was removed by filtration and the filtrate was evaporated. The residue was partitioned between EtOAc and dilute, aqueous HCl. The organic phase was separated, washed successively with brine and dilute, aqueous NaHCO<sub>3</sub>, dried (MgSO<sub>4</sub>), filtered, and evaporated. Purification by PLC [one development,  $C_6H_6$ -EtOAc (4:1)] yielded 18.5 mg (65%) of a mixture of **4a** and **4d.** See Table I1 for the isomer composition of this mixture, Table I for the NMR of the separated isomers, and below for further spectroscopic characterization and HPLC separation.

**Formation of 4a, 4b, and 4c by Reduction of 8b,c.** To a stirred suspension of excess  $Zn(Ag)^{10}$  in 1 mL of MeOH were added in rapid succession 75.6 mg (1.26 mmol) of neat glacial HOAc and a solution of 197.7 mg (0.48 mmol) of **8b.c** in 1 mL of MeOH. The mixture was stirred under  $N_2$  for 5 min and worked up as described above. PLC [one development,  $C_6H_6$ -EtOAc (3:1)] afforded 76 mg (48%) of a mixture of **4a, 4b,** and **4c.** See Tables I and **I1** and below for HPLC separation and further characterization.

Analogous reductions of **8b,c** with 0.5 and 2.5 equiv of HOAc and

without any HOAc gave the results depicted in Table **11.** 

**Formation of 4a, 4b, and 4d from Benzyl 6a-Iodopenicillanate (lob).** To a stirred solution of 2.01 g (4.82 mmol) of **10b** in 50 mL of dry Et<sub>2</sub>O at  $-73$  °C under N<sub>2</sub> atmosphere was added 2 mL (4.82) mmol) of 2.4 M BuLi in hexane. After 20 min at  $-73$  °C, 500  $\mu$ L (8.9) mmol) of neat MeCHO was added. The mixture was stirred at  $-73$ **"C** for 35 min and at **-40** "C for 30 min. The reaction **was** quenched at **-40** "C with 10 mL of saturated aqueous NH4Cl solution. The layers were separated and the aqueous phase further extracted with  $CH_2Cl_2$ . The extracts were combined and evaporated. The residue was redissolved in CH<sub>2</sub>Cl<sub>2</sub>, dried over MgSO<sub>4</sub>, filtered, and evaporated to give 2.04 g of residue. Purification by chromatography eluting with EtOAc (10-30%) in benzene yielded 811 mg **(50%)** of a mixture of **4a, 4b,** and **4d.** See Tables I and **I1** and below for HPLC purification and characterization.

The analogous reaction conducted with either **loa** or **10b** in THF provided irreproducible results and diminished yields of **4** (R = CH<sub>2</sub>Ph). See Table II.

 $S$ eparation of Isomers 4 ( $R = CH_2Ph$ ) by HPLC and Charac**terization. General.** All separations were performed on two 2 ft X 0.375 in. columns of Porosil A using 2% acetonitrile in chloroform (0.65% EtOH content) at a flow rate of 6 mL/min unless specified otherwise. Each purified isomer possessed identical carbonyl and hydroxyl absorptions in the infrared and identical mass spectral fragmentation patterns. Accordingly, a single data set is provided for **4a.** Every isomer was obtained as a colorless oil. GC retention times of the trimethylsilyl derivative prepared from ca. 1-2 mg of material and 2 drops of BSTFA in 1 drop of DMF were recorded at 230 "C. Consult Table **I** for NMR data.

**Isomer 4a.** A sample of 197.5 mg of a mixture of **4a** and **4d** having a composition of 95:5, respectively, was divided into approximately four equal aliquots and separated as described above to yield 146 mg of **4a:** IR 3700-3200,1776,1754 cm-' (sh); GC retention time 9.1 min; mass spectrum  $m/e$  335 (M<sup>+</sup>), 307, 250, 145, 114, 91; mass spectrum of Me3Si derivative *m/e* 407 **(M+),** 392,379,364,250.

**Isomer 4b.** A sample of 126.0 mg of composition **4a:4b** 60:40 obtained by removing the isomer **4d** by HPLC from a sample of isomers **4a, 4b,** and **4d** was used to obtain isomer **4b,** the most difficult to obtain. The entire sample was injected into six  $2 \text{ ft} \times 0.375$  in. columns of Porosil A using **1.5%** acetonitrile in chloroform (0.65% ethanol content) at a flow rate of 6 mL/min. All peaks were collected during cycle 1 except for the major peak, which was recycled through six columns a total of 22 times during 51 h. After seven cycles (with no evidence of peak asymmetry) small quantities were "shaved" from the front and back of the broad, large peak to obtain **4b** (front) and isomer **4a** (back). Five fractions obtained from shaving the front of the emerging peak at cycles 9,10,12,17, and 22 were combined after GC analysis of their Me3Si derivatives from aliquots to provide 22.9 mg of isomer **4b** (contained about **5%** of isomer **4a),** GC retention time 9.8 min.

**Isomer 4c.** A sample of 107 mg of a mixture of composition **4a:4b:4c**  18.6:40.3:41.1 was separated as described to give 27 mg of **4c,** GC retention time 11.3 min.

**Isomer 4d.** A sample of 239 mg of mixture of composition 4a:4b:4d 47:33:20 was divided into four equal portions and separated to provide 42 mg of **4d,** GC retention time 12.7 min.

General Procedure for the Formation of 6-(1'-Hydroxy**ethy1)penicillanic Acids 4a-d (R** = **H) and Their Sodium Salts**   $4 (R = Na)$ . To a stirred mixture of 150 mg of prereduced 10% Pd/C,  $2 \text{ mL of H}_2\text{O}$ ,  $10 \text{ mL of MeOH}$ , and  $1 \text{ mL of } 0.1 \text{ N } \text{NaHPO}_4$  buffer at room temperature was added a solution of a benzyl penicillanate in 3 mL of MeOH and the stirred mixture hydrogenated at atmospheric pressure for 0.5 h. The catalyst was removed by filtration through Solka-Floc and washed with MeOH. The filtrate was concentrated. The concentrate was diluted with  $H_2O$ , taken to pH 8.8 with dilute, aqueous NaHCO<sub>3</sub>, and extracted thoroughly with EtOAc. The separated aqueous phase was acidified to pH 3 with 2.5 N HCl and extracted with EtOAc. The EtOAc extract was dried with MgS04, filtered, and evaporated to afford pure acids  $4$   $(R = H)$  in yields of 70-80%. See Table I for NMR data.

The free acid was dissolved in acetone and treated with 1 equiv of aqueous NaHCO<sub>3</sub>. The acetone was removed under reduced pressure and the aqueous solution lyophilized to give quantitative yields of **4**   $(R = Na)$ .

**Isomer 4a (R = H):** mp 136-138 °C dec; IR (Nujol) 3400, 1780, 1774 cm-'; mass spectrum *m/e* 245 (M+), 217,201,159,114; mass spectrum bis-Me3Si *m/e* 374,361,346,232,143.

**Isomer 4c (R = H):** oil, IR 3700-3200, 1770, 1754 cm<sup>-1</sup> (sh).<br>**Isomer 4c (R = H):** oil, IR 3700-3200, 1770, 1754 cm<sup>-1</sup> (sh).

**Preparation of tert-Butyl7a-Iodocephalosporanate** ( **11** ). To

# Penicillanate and Cephalosporanate Enolates *J. Org. Chem., Vol. 42, No. 18,1977* **<sup>2965</sup>**

a stirred solution of tert-butyl 7-diazocephalosporanate from  $2.7 g$  $(8.4 \text{ mmol})$  of tert-butyl 7-aminocephalosporanate<sup>17</sup> by a modification of the procedure of Wiering and Wynberg<sup>18</sup> in 180 mL of acetone at 0-3 °C in an ice-H<sub>2</sub>O bath was added dropwise a cold solution of 3.7 mL of 57% HI and 4.76 g (31.8 mmol) of NaI in 15 mL of  $H_2O$  over 25 min. To the cold mixture was added solid  $NAHCO<sub>3</sub>$  and the insoluble materials were removed by filtration. The filtrate was evaporated and the residue was partitioned between 150 mL of EtOAc and 125 mL of 5% aqueous  $Na<sub>2</sub>S<sub>2</sub>O<sub>3</sub>$ . The organic phase was separated, dried over MgS04, filtered, and evaporated. Purification of the residue by column chromatography eluting initially with CHCl<sub>3</sub> and then  $C_6H_6-$ EtOAc (10:1) gave 1.0 g (27%) of 11 as an oil [IR 1778, 1717 cm<sup>-1</sup>; NMR  $\delta$  1.6 (s, 9 H), 2.1(s, 3 H), 3.47 (bs, 2 H), 4.7 (d, J = 12 Hz, 1 H), 4.83 (s, 2 H), 5.07 (d,  $J = 12$  Hz, 1 H); mass spectrum  $m/e$  383, 323, 256, 196, 155] and 220 mg of a mixture of 11 and the corresponding  $\beta$ -iodo isomer. Separation of this mixture by PLC [three developments,  $\rm C_6H_6$ -EtOAc (10:1)] gave 47 mg of 11 and 90 mg of tert-butyl 7 $\beta$ iodocephalosporanate: mp 100-102 °C dec (Et<sub>2</sub>O-petroleum ether); IR 1786, 1724 cm<sup>-1</sup>; NMR  $\delta$  1.57 (s, 9 H), 2.07 (s, 3 H), 3.4 (bs, 2 H),  $4.7$  (d,  $J = 12$  Hz, 1 H),  $4.77$  (d,  $J = 5$  Hz, 1 H),  $5.07$  (d,  $J = 12$  Hz, 1 H), 5.6 (d, *J* = 5 Hz, 1. HI; mass spectrum *mle* 383, 323, 256, 196, 155.

Formation of tert-Butyl  $7\alpha$ - and  $7\beta$ -(1'-Hydroxyethyl)cephalosporanates 5a,b and 5d. To a stirred solution of 11 (137.5 mg, 0.3 mmol) in 10 mL of dry  $Et_2O$  at  $-70^\circ$ C under a  $N_2$  atmosphere was added 108  $\mu$ L (0.3 mmol) of 2.9 M MeMgBr in Et<sub>2</sub>O. The mixture was stirred for 10 min and then exposed to a stream of anhydrous MeCHO for 15 min. The mixture was stirred at  $-70$  °C for 45 min and quenched with 1 mL of saturated NH<sub>4</sub>Cl solution. The mixture was partitioned between  $Et_2O$  and  $H_2O$  and the organic phase separated, dried (MgSO<sub>4</sub>), filtered, and evaporated. Purification of the residue by PLC [two developments,  $C_6H_6$ -EtOAc (4:1)] gave 19.0 mg (17%) of 5d [mp 154.5-155.5 °C (2-propanol); IR 3550 1770, 1732 cm<sup>-1</sup> NMR, see Table I; mass spectrum  $m/e$  357 (M<sup>+</sup>), 301, 241, 197, 155] and 27.5 mg (25%) of a mixture of 5a and 5b. Separation by fractional crystallization (2-propanol-petroleum ether) and HPLC gave a pure sample of the major trans diastereomer 5a: mp 124 °C; IR 3400, 1778, 1724 cm-'; NMR, see Table I; mass spectrum *mle* 301,241,197,155. No attempt was made to further purify the minor trans diastereomer 5b; however, the NMR data provided in Table I for 5b were obtained by a subtractive NMR comparison of pure 5a and an enriched sample of 5b.

General Procedure for the Conversion of tert-Butyl 7-(1'-**Hydroxyethy1)cephalosporanates** (5a and 5d) to the Free Acids 5a and 5d  $(\mathbf{R} = \mathbf{H})$  and Their Sodium Salts  $(\mathbf{R} = \mathbf{Na})$ . The tertbutyl cephalosporanate (0.08-0.09 mmol) was dissolved in 1 mL of cold  $CF_3CO_2H$  (TFA) and stirred at  $0^{\circ}C$  for 30 min. The TFA was removed under reduced pressure and the residue obtained partitioned between CHCl<sub>3</sub> and dilute, aqueous NaHCO<sub>3</sub> solution. The aqueous phase was separated and acidified to pH ca. 1-2 with 2.5 N HC1. The acidified mixture was thoroughly extracted with EtOAc. The combined EtOAc extracts were dried (MgS04), filtered, and evaporated to give the corresponding cephalosporanic acids which were characterized spectroscopically.

The cephalosporanic acid was dissolved in 3 mL of acetone and 1 mL of  $H_2O$  and treated with 1 equiv of NaHCO<sub>3</sub> in 0.5 mL of  $H_2O$  at room temperature for **5** min. The acetone was removed under reduced pressure and the aqueous solution lyophilized to yield the analogous sodium cephalosporanate.

**Isomer 5d** ( $\mathbf{R} = \mathbf{H}$ ): IR 1763, 1739 cm<sup>-1</sup>; NMR  $\delta$  1.27 (d,  $J = 6$  Hz,  $3 H$ ,  $2.03$  (s,  $3 H$ ),  $3.53$  (bs,  $2 H$ ),  $3.6$  (m,  $2 H$ ),  $4.6-5.23$  (m,  $3 H$ ); mass

spectrum (bis-Me<sub>3</sub>Si) *m/e* 445 (M<sup>+</sup>), 430, 385, 384, 215.<br> **Isomer 5a (R = H):** IR 3400, 1700, 1735 cm<sup>-1</sup>; NMR  $\delta$  1.3 (d, *J* = **6Hz,3H),2.1(~,3H),3.36(m,3H),4.4(m,lH),5.97(m,3H),6.5**  (bs, 2 H); mass spectrum (bis-Me<sub>3</sub>Si)  $m/e$  445 (M<sup>+</sup>), 430, 385, 227, 117.

**Acknowledgment.** We wish to thank Mr. J. Smith, Mr. H.

Flynn, and Dr. **B.** Arison for mass spectral and NMR measurements; Mr. J. P. Gilbert and staff for microanalytical determinations; Ms. J. Kahan for antibacterial evaluations; Dr. C. Shunk for the preparation of numerous starting materials; and Dr. Karst Hoogsteen and Mr. J. Hirshfield for the x-ray determination.

**Registry No.**-4a (R = CH<sub>2</sub>Ph), 62263-73-4; 4a (R = H), 62263-74-5; 4b  $(R = CH_2Ph)$ , 62263-75-6; 4b  $(R = H)$ , 62263-76-7; 4c  $(R = H)$  $CH_2Ph$ ), 62263-77-8; 4c  $(R = M)$ , 62263-78-9; 4d  $(R = CH_2Ph)$ , 62263-79-0; 4d  $(R = H)$ , 62263-80-3; 5a  $(R = CMe<sub>3</sub>)$ , 62279-92-9; 5a  $(R = H)$ , 62263-81-4; 5b  $(R = CMe<sub>3</sub>)$ , 62263-82-5; 5d  $(R = CMe<sub>3</sub>)$ , 62263-83-6; 5d  $(R = H)$ , 62263-84-7; 7, 35564-99-9; 8a, 62263-85-8; 8b, 62263-86-9; **8c,** 62263-87-0; 9,62263-88-1; loa, 62263-89-2; lob, 62263-90-5; 11,62263-70-1; 11 8-iodo isomer, 62263-71-2; benzyl diazopenicillanate, 20097-92-1; **tert-butyldimethylchlorosilane,**  18162-48-6; benzyl penicillanate, 62263-72-3; tert- butyl 7-diazocephalosporanate, 58249-92-6.

#### **References and Notes**

- (1) (a) J. *8.* Kahan, F. **M.** Kahan, **R.** Goegelman, S. A. Cwrie, **M.** Jackson, E. 0. Stapley, T. W. Miller, A. K. Miller, D. Hendlin, S. **Mochales,** S. **Hernandez,**  and H. **B.** Woodruff, Abstracts, XVlth lnterscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, III., Oct 1976, No. 227; (b) H.<br>Kropp, J. S. Kahan, F. M. Kahan, J. Sundelof, G. Darland, and J. Birnbaum,<br>*ibid.*, No. 228; (c) G. Albers-Schönberg, B. H. Arison, E. Kaczka, F. M. Kahan. J. S. Kahan, E. Lago, W. **M.** Maiese, **R.** E. Rhodes, and J. L. Smith, ibid., No. 229.
- (2) Previously 6a-( **1'-hydroxyethyl)penicillin** V had been reported: G. H. Ras- musson. G. **F.** Reynolds, and G. **E.** Arth, Tetrahedron Lett., 145 (1973).
- (3) It should be noted that enolates of simple monocyclic azetidinones [T. and **M.** J. LeBelle, *Can. J.* Chem., **50,** 3196 (1972)] and 4,4disubstituted A-2-cepherns [K. Kuhlein and *H.* Jensen, *Justus Lie6i@* Ann. *Chem.,* 369 (1974)] have been generated with strong dialkylamide **bases. For** similarly useful dianions of monocyclic azetiiinones, **see** T. Dwst. **R.** Van Den Elzen, and R. Legault, *Can. J. Chem.*, 52, 3206 (1974). Further, it is denoted that the well-known<sup>4</sup> Schiff base enolates (e.g.,  $X = N = CHPh$ ) are not applicable in this context since methodology for the reductive removal of the amino function remains unknown.
- (4) For a recent review of these works see A. K. Mukerjee and A. K. Singh, Synthesis, 547 (1975).
- (5) J. P. Clayton, *J. Chem. SOC. C,* 2123 (1969). (6) For a minireview on the preparation and applications of a-halo enolates, see H. Normant, *J.* Organomet. Chem., 100, 189 (1975).
- (7) L. D. Cama. W. J. Leanza, T. **R.** Beattie, and **B.** G. Christensen, *J.* Am. *Chem. SOC.,* **95,** 1408 (1972).
- 
- 
- (8) Details of this analysis will be published at a later date.<br>(9) E. J. Corey and A. Venkateswarlu, *J. Am. Chem. Soc.,* 94, 6190 (1972).<br>10) C. H. Heathcock and R. D. Clark, *J. Org. Chem.*, **38,** 3658 (1973); 41, 636 (1976).
- 11) **R** was shown that the absolute configuration of the hydroxyethyl side chain was not *unexpectedly* altered during reduction by utilizing the method of Mosher<sup>12</sup> on isomer 4a. For this determination we are indebted to Dr. R.
- Ratcliffe of these laboratories. 12) J. A. Dale, D. L. Dull, and H. S. Mosher, *J.* Org. *Chem.,* 34, 2543 (1969); J. A. Dale and H. S. Mosher, *J.* Am. Chem. Soc., **95,** 512 (1973). For other recent applications of this method see J. S. Dutcher and C. H. Heathcock,<br>Tetrahedron Lett., 933 (1974); W. G. Dauben, G. Lodder, and J. D. Robbins,<br>J. Am. Chem. Soc., 98, 3030, 1976; K. Mori, T. Takigawa, and M. Matsui,<br>T
- 
- 
- contaminated with variable amounts of benzyl alcohol and a butyl ketone component identified as A.



- **A**  (1 7) **R.** J. Stedman, *J.* Med. Chem., **9,** 444 (1 966).
- (18) J. S. Wiering and H. Wynberg, *J.* Org. *Chem.,* 41, 1574 (1976).